KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in early Non-Small Cell Lung Cancer
Eklund, E. A.; Mourad, A.; Wiel, C.; Fagman, H.; Hallqvist, A.; Sayin, V. I.
Show abstract
BackgroundKRAS mutation status, stage and tumor size at the time of diagnosis are well-established independent prognostic factors in non-small cell lung cancer (NSCLC). Here, we investigate the prognostic value of combining survival data on KRAS mutation status and tumor size in early-stage NSCLC. MethodsWe studied the combined impact of KRAS mutational status and tumor size on overall survival (OS) and risk of death in patients with stage I-II NSCLC. We performed a retrospective study including 310 consecutively diagnosed patients with early (stage I-II) NSCLCs. All consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage I-II NSCLC in the Vastra Gotaland region of western Sweden were included in this multi-center retrospective study. The primary study outcome was OS and risk of death (hazard ratio). ResultsOut of 310 patients with stage I-II NSCLC, 37% harbored an activating mutation in the KRAS gene. Our study confirmed staging and tumor size as prognostic factors. However, KRAS mutational status was not found to impact OS and there was no difference in the risk of death when combining KRAS mutational status and primary tumor size. ConclusionsIn our patient cohort, KRAS mutations in combination with primary tumor size are not associated with a worse prognosis in stage I-II NSCLC.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer 96%
- Dysregulation of lncRNA MALAT1 Contributes to Lung Cancer in African Americans by modulating the tumor immune microenvironment 93%
- A novel role for the tumor suppressor gene ITF2 in lung tumorigenesis and chemotherapy response 93%
Similar papers in this journal
- Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors 93%
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 92%
- Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy 92%
Similar papers in this journal
- Insulin-like Growth Factor 1 Receptor Expression Correlates with Programmed Death Ligand 1 Expression and Poor Survival in Non-small Cell Lung Cancer 94%
- Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study 93%
- Survival benefits of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study 92%
Similar papers in this journal
- RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236 94%
- Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation 93%
- High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma 91%
Similar papers in this journal
- Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasis 95%
- Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer 92%
- Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Cancers Identifies KMT2C as a Potential Tumor Suppressor 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.